Mustang Bio Revenue and Competitors
Estimated Revenue & Valuation
- Mustang Bio's estimated annual revenue is currently $16.4M per year.
- Mustang Bio's estimated revenue per employee is $167,653
- Mustang Bio's total funding is $129.3M.
Employee Data
- Mustang Bio has 98 Employees.
- Mustang Bio grew their employee count by 9% last year.
Mustang Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | CTO | Reveal Email/Phone |
2 | SVP Preclinical Science | Reveal Email/Phone |
3 | VP, General Counsel and Corporate Secretary | Reveal Email/Phone |
4 | VP, Clinical Affairs | Reveal Email/Phone |
5 | VP Operations | Reveal Email/Phone |
6 | VP, Program & Alliance Leadership | Reveal Email/Phone |
7 | SVP Human Resources | Reveal Email/Phone |
8 | SVP, Finance & Corporate Controller | Reveal Email/Phone |
9 | Controller | Reveal Email/Phone |
10 | Head Regulatory Affairs | Reveal Email/Phone |
Mustang Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46850M | 145000 | 16% | $20.2B | $539B |
What Is Mustang Bio?
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinicalâ€stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COHâ€) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang's lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
keywords:N/A$129.3M
Total Funding
98
Number of Employees
$16.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mustang Bio News
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non...
Mustang Bio's CAR T Cell Therapy Shows Favorable Safety Profile, Response Rates In Blood Cancer Patients ... [TODAY ONLY] Get 50% OFF and get 2...
WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.3M | 99 | 4% | N/A |
#2 | $28.7M | 99 | 62% | N/A |
#3 | $10.1M | 99 | 9% | N/A |
#4 | $16.3M | 99 | N/A | N/A |
#5 | $18M | 100 | 16% | N/A |